Prague Med. Rep. 2022, 123, 65-81
https://doi.org/10.14712/23362936.2022.7
Liposteroid Therapy for Idiopathic Pulmonary Hemosiderosis: A Scoping Review of the Literature
References
1. 2001) Idiopathic pulmonary hemosiderosis in an adult. Favourable response to azathioprine. Monaldi Arch. Chest Dis. 56(3), 211–213.
, L., Ciceri, L., Giannini, S., Ferrero, S., Meroni, P. L., Tedeschi, A. (
2. 1998) Idiopathic pulmonary haemosiderosis. Favourable effect of corticosteroids in two women aged 16 and 55 years. Eur. Respir. Topic 4, 53–57.
, A. M., Milman, N., Clausen, P. P., Reinert, P., Pedersen, F. M., Jacobsen, G. K. (
3. 2018) Pulmonary hemosiderosis in children with Down syndrome: A national experience. Orphanet J. Rare Dis. 13(1), 60.
< , A., Taytard, J., Abou Taam, R., Houdouin, V., Forgeron, A., Lubrano Lavadera, M., Cros, P., Gibertini, I., Derelle, J., Deschildre, A., Thumerelle, C., Epaud, R., Reix, P., Fayon, M., Roullaud, S., Troussier, F., Renoux, M.-C., de Blic, J., Leyronnas, S., Thouvenin, G., Perisson, C., Ravel, A., Clement, A., Corvol, H., Nathan, N.; French RespiRare® Group (https://doi.org/10.1186/s13023-018-0806-6>
4. 1993) Liposome-incorporated dexamethasone palmitate: Chemical and physical properties. Int. J. Pharm. 89(3), 157–167.
< , H., De Gand, G., Brasseur, R., Van Vooren, J. P., Legros, F. J. (https://doi.org/10.1016/0378-5173(93)90239-C>
5. 2008) Hematologic malignant neoplasms after drug exposure in rheumatoid arthritis. Arch. Intern. Med. 168(4), 378–381.
< , S., Clarke, A. E., Suissa, S. (https://doi.org/10.1001/archinternmed.2007.107>
6. 2002) Recurrence of idiopathic pulmonary hemosiderosis in a young adult patient after bilateral single-lung transplantation. Transplantation 74(11), 1643–1645.
< , F., Giacometti, C., Rea, F., Loy, M., Sartori, F., Di Vittorio, G., Abudureheman, A., Thiene, G., Valente, M. (https://doi.org/10.1097/00007890-200212150-00027>
7. 2017) Idiopathic pulmonary hemosiderosis in adults: Review of cases reported in the latest 15 years. Clin. Respir. J. 11(6), 677–681.
< , X.-Y., Sun, J.-M., Huang, X.-J. (https://doi.org/10.1111/crj.12440>
8. 2015) A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis. Orphanet J. Rare Dis. 10, 98.
< , C. I. C., Kohn, S. L., Keens, T. G., Margetis, M. F., Kato, R. M. (https://doi.org/10.1186/s13023-015-0319-5>
9. 1992) Treatment of life-threatening primary pulmonary hemosiderosis with cyclophosphamide. Chest 102(3), 959–960.
< , J. L., Stolz, S. M. (https://doi.org/10.1378/chest.102.3.959>
10. 2013) Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur. J. Pediatr. 172(11), 1475–1481.
< , T., Ohga, S., Ishimura, M., Takada, H., Ishii, K., Ihara, K., Nagai, H., Hara, T. (https://doi.org/10.1007/s00431-013-2065-9>
11. 2015) Erratum to: Long-term liposteroid therapy for idiopathic pulmonary hemosiderosis. Eur. J. Pediatr. 174(12), 1701.
< , T., Ohga, S., Ishimura, M., Takada, H., Ishii, K., Ihara, K., Nagai, H., Hara, T. (https://doi.org/10.1007/s00431-015-2638-x>
12. 2010) Histiocytic disorders: Recent insights into pathophysiology and practical guidelines. Biol. Blood Marrow Transplant. 16, S82–S89 (Suppl. 1).
< , A., McClain, K., Grom, A. (https://doi.org/10.1016/j.bbmt.2009.11.014>
13. 2013) Successful treatment of idiopathic pulmonary capillaritis with intravenous cyclophosphamide. Pediatr. Pulmonol. 48(3), 303–305.
< , F., Glackin, L., Slattery, D. M. (https://doi.org/10.1002/ppul.22583>
14. 2015) Chronic alveolar haemorrhage in a paediatric patient: A diagnostic and treatment challenge. BMJ Case Rep. 2015, bcr2014206856.
< , A., Senra, V., Marinho, A., Guedes, M. (https://doi.org/10.1136/bcr-2014-206856>
15. 2005) Pulmonary capillaritis in children: A review of eight cases with comparison to other alveolar hemorrhage syndromes. J. Pediatr. 146(3), 376–381.
< , J. J., Langston, C., Dishop, M. K., Fan, L. L. (https://doi.org/10.1016/j.jpeds.2004.10.025>
16. 2003) Effects of liposteroid on the hemophagocytic syndrome in systemic lupus erythematosus. Lupus 12(6), 483–485.
< , M., Ohno, M., Yamagata, T., Nozaki, Y., Kinoshita, K., Kanamaru, A. (https://doi.org/10.1191/0961203303lu373oa>
17. Furst, D. E., Saag, K. G. (2021) Determinants of glucocorticoid dosing. UpToDate. Retrieved January 22, 2021, from: https://www.uptodate.com/contents/determinants-of-glucocorticoid-dosing?search=relative %20potency%20of%20corticosteroids&source=search_result&selectedTitle=1~150&usage_type =default&display_rank=1
18. 2021) A case of idiopathic pulmonary hemosiderosis associated with emphysematous change in an adult who underwent lung transplantation. Intern. Med. 60(1), 117–122.
< , K., Sato, K., Imasaka, K., Hamanaka, N., Takahashi, M., Shimizu, K., Takemura, T. (https://doi.org/10.2169/internalmedicine.5142-20>
19. 2014) Extracorporeal life support for a 5-week-old infant with idiopathic pulmonary hemosiderosis. Eur. J. Pediatr. 173(12), 1573–1576.
< , S., Shaw, S., Huseni, S., Sachdeva, S., Costello, J. P., Basu, S., Nath, D. S., Klugman, D. (https://doi.org/10.1007/s00431-013-2130-4>
20. 2003) Management of idiopathic pulmonary haemosiderosis in pregnancy: Report of two cases. Respirology 8(3), 398–400.
< , D. L., Sullivan, A., Kariya, S. T., Deering, S. H., Hueppchen, N. A., Shorr, A. F. (https://doi.org/10.1046/j.1440-1843.2003.00477.x>
21. 1985) Double-blind study with liposteroid in rheumatoid arthritis. Drugs Exp. Clin. Res. 11(9), 621–626.
, K., Mizushima, Y., Shiokawa, Y., Kageyama, T., Honma, M., Kashiwazaki, S., Shichikawa, K., Tsunematsu, T., Kaneko, K. (
22. 1988) A case of idiopathic pulmonary hemosiderosis recurrent after remission of fifteen years and associated with Sjögren’s syndrome. Nihon Kyobu Shikkan Gakkai Zasshi 26(11), 1191–1194. (in Japanese)
, N., Torii, Y., Ito, S., Hiramatu, K., Suzuki, M., Ito, T., Senda, Y. (
23. 2019) A case of acute life-threatening pulmonary hemorrhage from synthetic cannabinoid abuse. Case Rep. Pulmonol. 2019, 8137648.
, M., Saha, B., Sana Ullah, U., Saha, A. (
24. 2004) Idiopathic pulmonary haemosiderosis revisited. Eur. Respir. J. 24(1), 162–169.
< , O. C., Sieber, S., Kotch, A. (https://doi.org/10.1183/09031936.04.00116302>
25. 2009) Idiopathic pulmonary hemosiderosis in a 9-year-old girl. Eur. J. Med. Res. 14, 112–115 (Suppl. 4).
< , E., Urasinski, T., Gawlikowska-Sroka, A., Glura, B., Pogorzelski, A. (https://doi.org/10.1186/2047-783X-14-S4-112>
26. 1999) Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979–1994): Prolonged survival with low-dose corticosteroid therapy. Pediatr. Pulmonol. 27(3), 180–184.
< , N., Göçmen, A., Özçelik, U., Dilber, E., Anadol, D. (https://doi.org/10.1002/(SICI)1099-0496(199903)27:3<180::AID-PPUL5>3.0.CO;2-8>
27. 1984) Idiopathic pulmonary haemosiderosis in Swedish children. Acta Paediatr. 73(5), 584–588.
< , B., Elinder, G., Garwicz, S., Svan, H. (https://doi.org/10.1111/j.1651-2227.1984.tb09978.x>
28. 2007) Successful treatment with liposteroid followed by reduced intensity stem cell transplantation in an infant with perforin deficiency presenting with hemophagocytic lymphohistiocytosis. J. Pediatr. Hematol. Oncol. 29(3), 178–182.
< , Y., Salih, H. M., Kajiume, T., Nakamura, K., Miyagawa, S., Sato, T., Nishimura, S., Kobayashi, M. (https://doi.org/10.1097/MPH.0b013e3180335030>
29. 2019) The effect of palmitic acid on inflammatory response in macrophages: An overview of molecular mechanisms. Inflamm. Res. 68(11), 915–932.
< , J., Bajdak-Rusinek, K. (https://doi.org/10.1007/s00011-019-01273-5>
30. 2017) Methylprednisolone pulse therapy rescued life-threatening pulmonary hemorrhage due to idiopathic pulmonary hemosiderosis. Am. J. Emerg. Med. 35(11), 1786.e3–1786.e7.
< , Y.-T., Guo, Y.-X., Cai, L.-M., Pan, L., Duan, M.-Q., Yang, L.-F., Sun, Y.-Y., Tan, W.-P., Chen, Z.-G. (https://doi.org/10.1016/j.ajem.2017.07.094>
31. 2019) Extracorporeal membrane oxygenation for diffuse alveolar hemorrhage caused by idiopathic pulmonary hemosiderosis: A case report and a review of the literature. J. Pediatr. Intensive Care 8(3), 181–186.
, S., Nakagawa, S. (
32. Milman, N. (2020) Idiopathic pulmonary hemosiderosis. UpToDate. Retrieved October 11, 2020, from: https://www.uptodate.com/contents/idiopathic-pulmonary-hemosiderosis?search=idiopathic %20pulmonary%20hemosiderosis§ionRank=1&usage_type=default&anchor=H17&source =machineLearning&selectedTitle=1~17&display_rank=1#H17
33. 1998) Idiopathic pulmonary haemosiderosis. Epidemiology, pathogenic aspects and diagnosis. Respir. Med. 92(7), 902–907.
< , N., Pedersen, F. M. (https://doi.org/10.1016/S0954-6111(98)90188-3>
34. 1982) Tissue distribution and anti-inflammatory activity of corticosteroids incorporated in lipid emulsion. Ann. Rheum. Dis. 41(3), 263–267.
< , Y., Hamano, T., Yokoyama, K. (https://doi.org/10.1136/ard.41.3.263>
35. 1983) Targeting steroid therapy in rheumatoid arthritis. Ann. Rheum. Dis. 42(4), 479–480.
< , Y., Kaneko, K., Hoshi, K. (https://doi.org/10.1136/ard.42.4.479>
36. 2006) Life threatening exacerbation in idiopathic pulmonary hemosiderosis salvaged by cyclophosphamide infusion. Indian J. Chest Dis. Allied Sci. 48(4), 287–289.
, R., Chandra, J., Singh, V., Kumar, V., Dubey, N. K. (
37. 2009) Impact of macrophage infiltration of skin lesions on survival after allogeneic stem cell transplantation: A clue to refractory graft-versus-host disease. Blood 114(14), 3113–3116.
< , S., Terakura, S., Ito, M., Goto, T., Seto, A., Watanabe, K., Yanagisawa, M., Imahashi, N., Tsukamoto, S., Shimba, M., Ozawa, Y., Miyamura, K. (https://doi.org/10.1182/blood-2009-03-209635>
38. 2014) Dexamethasone palmitate ameliorates macrophages-rich graft-versus-host disease by inhibiting macrophage functions. PLoS One 9(5), e96252.
< , S., Nakayama, T., Murata, M., Nishida, T., Terakura, S., Saito, S., Kato, T., Mizuno, H., Imahashi, N., Seto, A., Ozawa, Y., Miyamura, K., Ito, M., Takeshita, K., Kato, H., Toyokuni, S., Nagao, K., Ueda, R., Naoe, T. (https://doi.org/10.1371/journal.pone.0096252>
39. 1994) Liposteroid against refractory pulmonary haemorrhage in idiopathic pulmonary haemosiderosis. Eur. J. Pediatr. 153(9), 687–690.
< , S., Nomura, A., Suga, N., Hikino, S., Kira, R., Matsuzaki, A., Ueda, K., Masuda, K. (https://doi.org/10.1007/BF02190693>
40. 1995) Idiopathic pulmonary haemosiderosis in Japan: 39 possible cases from a survey questionnaire. Eur. J. Pediatr. 154(12), 994–995.
< , S., Takahashi, K., Miyazaki, S., Kato, H., Ueda, K. (https://doi.org/10.1007/BF01958645>
41. 1995) Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study. Arthritis Rheum. 38(8), 1120–1127.
< , C. D., Kahl, L. E., Baker, G. L., Wasko, M. C., Cash, J. M., Gallatin, A., Stolzer, B. L., Agarwal, A. K., Medsger, T. A., Kwoh, C. K. (https://doi.org/10.1002/art.1780380815>
42. 2020) Disease recurrence after lung transplantation for idiopathic pulmonary hemosiderosis. Respir. Med. Case Rep. 30, 101128.
, B., Halloran, K., Adam, B., Laing, B., Hirji, A. (
43. 1992) Long-term prednisone and azathioprine treatment of a patient with idiopathic pulmonary hemosiderosis. Pediatr. Pulmonol. 13(3), 176–180.
< , G. A., Balzano, E., Battistini, E., Oddera, S., Marchese, P., Acquila, M., Fregonese, B., Mori, P. G. (https://doi.org/10.1002/ppul.1950130310>
44. 1999) Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest 116(3), 721–725.
< , M. M., Woo, M. S., MacLaughlin, E. F., Margetis, M. F., Keens, T. G. (https://doi.org/10.1378/chest.116.3.721>
45. 2020) Idiopathic pulmonary hemosiderosis: A state of the art review. Respir. Med. 176, 106234.
< , B. K. (https://doi.org/10.1016/j.rmed.2020.106234>
46. 2021) Is it time to call idiopathic pulmonary hemosiderosis by the correct name: Immune-mediated pulmonary hemosiderosis? Am. J. Med. Sci. 361(6), 809–811.
< , B. K. (https://doi.org/10.1016/j.amjms.2021.01.006>
47. 2021) Diffuse alveolar hemorrhage in cardiac diseases. Lung 199(2), 103–112.
< , B. K., Chong, W. H. (https://doi.org/10.1007/s00408-021-00433-x>
48. 2022) Lung transplant to manage end-stage lung disease due to idiopathic pulmonary hemosiderosis: A review of the literature. Respir. Investig. 60(1), 82–89.
< , B. K., Chong, W. H. (https://doi.org/10.1016/j.resinv.2021.06.009>
49. 2021a) Idiopathic pulmonary hemosiderosis: A review of the treatments used during the past 30 years and future directions. Clin. Rheumatol. 40(7), 2547–2557.
< , B. K., Milman, N. T. (https://doi.org/10.1007/s10067-020-05507-4>
50. 2021b) Short review of liposteroid: A novel targeted glucocorticoid preparation for treatment of autoimmune and inflammatory diseases. Prague Med. Rep. 122(4), 257–268.
< , B. K., Milman, N. T. (https://doi.org/10.14712/23362936.2021.23>
51. 2022) Differentiation of idiopathic pulmonary hemosiderosis from rheumatologic and autoimmune diseases causing diffuse alveolar hemorrhage: Establishing a diagnostic approach. Clin. Rheumatol. 41(2), 325–336.
< , B. K., Chong, W. H., Milman, N. T. (https://doi.org/10.1007/s10067-021-05895-1>
52. 2021) Unilateral diffuse alveolar hemorrhage due to selective directionality of mitral regurgitant jet in a patient with severe aortic stenosis. Cureus 13(4), e14714.
, S., Chong, W. H., Saha, B. K. (
53. 2018) Liposteroid and methylprednisolone combination therapy for a case of idiopathic lung hemosiderosis. Respir. Med. Case Rep. 24, 22–24.
, R., Matsumoto, S., Mitsubuchi, H., Nakamura, K. (
54. 1995) Successful treatment with liposteroid in an infant case of idiopathic pulmonary hemosiderosis. 日本小児血液学会雑誌 9, 42–46. (in Japanese)
, Y., Kamisue, S., Shima, M., Yoshioka, A. (
55. 1999) Liposteroid therapy for chronic childhood idiopathic thrombocytopenic purpura: Two case reports. Int. J. Pediatr. Hematol. 6, 27–31.
, Y., Ohkubo, Y., Miura, S., Mariko, M., Akazawa, H., Imanaka, Y., Kinoshita, S., Yoshioka, A. (
56. 2006) Therapeutic application of long-circulating liposomal glucocorticoids in auto-immune diseases and cancer. J. Liposome Res. 16(3), 185–194.
< , R. M., Banciu, M., Metselaar, J. M., Storm, G. (https://doi.org/10.1080/08982100600851029>
57. 1962) Idiopathic pulmonary hemosiderosis and related syndromes. Am. J. Med. 32(4), 499–511.
< , K. H., Sommers, S. C. (https://doi.org/10.1016/0002-9343(62)90051-7>
58. 2019) Diffuse alveolar haemorrhage associated with subsequent development of ANCA positivity and emphysema in three young adults. BMC Pulm. Med. 19(1), 185.
< , A., Rice, A., Devaraj, A., Barnett, J. L., Donovan, J., Kokosi, M., Nicholson, A. G., Cairns, T., Wells, A. U., Renzoni, E. A. (https://doi.org/10.1186/s12890-019-0947-y>
59. 2013) New insights into pediatric idiopathic pulmonary hemosiderosis: The French RespiRare(®) cohort. Orphanet J. Rare Dis. 8, 161.
< , J., Nathan, N., de Blic, J., Fayon, M., Epaud, R., Deschildre, A., Troussier, F., Lubrano, M., Chiron, R., Reix, P., Cros, P., Mahloul, M., Michon, D., Clement, A., Corvol, H.; French RespiRare® Group (https://doi.org/10.1186/1750-1172-8-161>
60. 2016) Biopsy-proven pulmonary capillaritis: A retrospective study of aetiologies including an in-depth look at isolated pulmonary capillaritis. Respirology 21(4), 734–738.
< , G., Klecka, M., Roden, A. C., Specks, U., Cartin-Ceba, R. (https://doi.org/10.1111/resp.12738>
61. 2020) Successful liposteroid therapy for a recurrent idiopathic pulmonary hemosiderosis with Down syndrome. Case Rep. Pediatr. 2020, 5292977.
, H., Yano, J., Sato, N., Amanuma, F., Takahashi, M., Endo, M., Ishimura, M., Ohga, S., Maruyama, H. (
62. Virchow, R. (1864) Krankhaften Geshwülste. Hirschwald, Berlin.
63. 2016) Clinical utility of the liposteroid therapy: Potential effects on the macrophage activation. Nihon Rinsho Meneki Gakkai Kaishi 39(3), 190–196.
< , H., Ohga, S. (https://doi.org/10.2177/jsci.39.190>
64. 2015) Successful control of juvenile dermatomyositis-associated macrophage activation syndrome and interstitial pneumonia: Distinct kinetics of interleukin-6 and -18 levels. Pediatr. Rheumatol. Online J. 13, 49.
< , H., Hasegawa, S., Hirano, R., Kaneyasu, H., Wakabayashi-Takahara, M., Ohga, S. (https://doi.org/10.1186/s12969-015-0048-2>
65. 2015) Idiopathic pulmonary hemosiderosis complicated by Down syndrome. Pediatr. Int. 57(5), 1009–1012.
< , H., Ayusawa, M., Kato, M., Chou, A., Komori, A., Abe, Y., Matsumura, M., Kamiyama, H., Izumi, H., Takahashi, S. (https://doi.org/10.1111/ped.12690>
66. 1997) The challenges of idiopathic pulmonary hemosiderosis and lung transplantation. Crit. Care Nurse 17(3), 39–44.
< , B. M., Stefanovic, C. R., McDonough, V. M., Kidik, P. J. (https://doi.org/10.4037/ccn1997.17.3.39>
67. 2018) Recurrent idiopathic pulmonary hemosiderosis after long-term remission presented with Sjogren’s syndrome: Idiopathic no more? Respir. Med. Case Rep. 25, 68–72.
, T., Yamamoto, Y., Hamada, N., Suzuki, K., Ogata-Suetsugu, S., Harada, E., Tagawa, T., Fujiwara, M., Hashisako, M., Fukuoka, J., Nakanishi, Y. (
68. 1996) Limethason as a lipid microsphere preparation: An overview. Adv. Drug Deliv. Rev. 20(2), 195–201.
< , K., Watanabe, M. (https://doi.org/10.1016/0169-409X(95)00122-N>
69. 1985) Development of a corticosteroid incorporated in lipid microspheres (liposteroid). Drugs Exp. Clin. Res. 11(9), 611–620.
, K., Okamoto, H., Watanabe, M., Suyama, T., Mizushima, Y. (
70. 2019) Clinical characteristics and prognosis of idiopathic pulmonary hemosiderosis in pediatric patients. J. Int. Med. Res. 47(1), 293–302.
< , Y., Luo, F., Wang, N., Song, Y., Tao, Y. (https://doi.org/10.1177/0300060518800652>